Cantor Fitzgerald Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)
Cantor Fitzgerald analyst Olivia Brayer maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a ...
Business Insider20h
Cantor Fitzgerald Sticks to Their Buy Rating for Nyxoah (NYXH)
In a report released yesterday, Ross Osborn from Cantor Fitzgerald reiterated a Buy rating on Nyxoah (NYXH – Research Report), with a price target of $16.00. The company’s shares closed yesterday at ...